Testing how two drugs change tumor chemistry in people with glioma
Original title: Intratumoral Extracellular Metabolic Impact of DFMO and AMXT 1501 in Patients With Diffuse or High Grade Glioma
How far along is this research?
This is a trial that is enrolling or has been updated. It is not a finding yet.
This is an early first test of these drugs in people.
Status: Recruiting. It is looking for patients now. Talk to your care team about whether it fits you.
The trial team last updated this record on . Always check the trial page for the latest.
The short version
This study tests how two drugs change the chemistry inside a brain tumor.
Who this trial is for. This early study is for people with diffuse or high grade glioma: A tumor that starts in the glial cells. Those are the support cells of the brain and spinal cord. Gliomas are given a grade from 1 to 4. The grade says how the tumor is expected to act. See the glossary. It tests two drugs, DFMO and AMXT 1501.
Where it stands. The study measures the molecules in the fluid inside the tumor. The goal is to see how the two drugs change that. The trial has not reported results.
What this means, and what it doesn't
What it could mean: Brain tumors use and make certain molecules to live and grow. This study looks at drugs that act on those molecules. Someone who fits might ask their care team about it.
What it doesn't mean: This does not mean these drugs work. A trial is a test, not a proven treatment. Joining one is not a promise of help. It is not a cure.
Source: ClinicalTrials.gov, November 4, 2026 · Read the original
This plain-language summary was written by AI and published automatically after passing our automatic safety checks. How we write.